Document:

EXHIBIT 4.2

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE
REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY,
THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES,
OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.

 

INTERLEUKIN GENETICS,
INC. 

 

WARRANT TO PURCHASE 2,492,523
SHARES

OF COMMON STOCK

 

THIS CERTIFIES THAT, for value
received, HORIZON TECHNOLOGY FINANCE CORPORATION and its assignees are entitled to subscribe for and purchase  2,492,523 shares
of the fully paid and nonassessable Common Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of
INTERLEUKIN GENETICS, INC., a Delaware corporation (the “Company”), at the price of $0.1003 per share (such price
and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein
referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set
forth. As used herein, (a) the term “Date of Grant” shall mean December 23, 2014, and (b) the term
“Other Warrants” shall mean any other warrants issued by the Company in connection with the transaction with
respect to which this Warrant was issued, and any warrant issued upon transfer or partial exercise of or in lieu of this
Warrant. The term “Warrant” as used herein shall be deemed to include Other Warrants unless the context clearly
requires otherwise.

 

1.          Term.
The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from the
Date of Grant through ten (10) years after the Date of Grant (the “Term”).

 

2.          Method
of Exercise; Payment; Issuance of New Warrant. Subject to Section 1 hereof, the purchase right represented by this Warrant
may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a) the
surrender of this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed
and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire
transfer to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant
Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of the
Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2
duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably satisfactory
to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of
shares to be sold by the holder in such public offering of an amount equal to the then applicable Warrant Price per share multiplied
by the number of Shares then being purchased; or (c) exercise of the “net issuance” right provided for in Section
10.2 hereof. The person or persons in whose name(s) any certificate(s) representing the Shares shall be issuable upon exercise
of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record
holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close
of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of the rights represented by
this Warrant, certificates for the shares of stock so purchased shall be delivered to the holder hereof as soon as possible and
in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant
representing the portion of the Shares, if any, with respect to which this Warrant shall not then have been exercised shall also
be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time
as the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, if requested by
the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon
exercise of this Warrant to a broker or other person (as directed by the holder exercising this Warrant) within the time period
required to settle any trade made by the holder after exercise of this Warrant.

 

    	 

    	 

    

 

3.          Stock
Fully Paid; Reservation of Shares. All Shares that may be issued upon the exercise of the rights represented by this Warrant
will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive
rights and taxes, liens and charges with respect to the issue thereof. During the period within which the rights represented by
this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise
of the purchase rights evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise
of the rights represented by this Warrant.

 

4.          Adjustment
of Warrant Price and Number of Shares. The number and kind of securities purchasable upon the exercise of this Warrant and
the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:

 

(a)          Reclassification
or Merger. In case of any reclassification or change of securities of the class issuable upon exercise of this Warrant (other
than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision
or combination), or in case of any merger of the Company with or into another corporation (other than a merger with another corporation
in which the Company is the acquiring and the surviving corporation and which does not result in any reclassification or change
of outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets
of the Company, the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to
the holder of this Warrant a new Warrant (in form and substance satisfactory to the holder of this Warrant), so that the holder
of this Warrant shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable
upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Common Stock theretofore issuable upon
exercise of this Warrant, (i) the kind and amount of shares of stock, other securities, money and property receivable upon
such reclassification, change, merger or sale by a holder of the number of shares of Common Stock then purchasable under this Warrant,
or (ii) in the case of such a merger or sale in which the consideration paid consists all or in part of assets other than
securities of the successor or purchasing corporation, at the option of the holder of this Warrant, the securities of the successor
or purchasing corporation having a value at the time of the transaction equivalent to the value of the Common Stock purchasable
upon exercise of this Warrant at the time of the transaction. Any new Warrant shall provide for adjustments that shall be as nearly
equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this Section 4(a) shall
similarly apply to successive reclassifications, changes, mergers and sales.

 

    	-2-

    	 

    

 

 

(b)          Subdivision
or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or
combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased and the number of Shares issuable
hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased
and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination.

 

(c)          Stock
Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay
a dividend with respect to its Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the
date of determination of shareholders entitled to receive such dividend or distribution, to that price determined by multiplying
the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall
be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the
denominator of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution;
or (ii) make any other distribution with respect to Common Stock (except any distribution specifically provided for in Sections 4(a)
and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall receive upon
exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Shares
as of the record date fixed for the determination of the shareholders of the Company entitled to receive such dividend or distribution.

 

(d)          Adjustment
of Number of Shares. Upon each adjustment in the Warrant Price, the number of Shares purchasable hereunder shall be adjusted,
to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment
in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and
the denominator of which shall be the Warrant Price immediately thereafter.

 

5.          Notice
of Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to Section 4
hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event
requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price
and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate
to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant.

 

    	-3-

    	 

    

 

6.          Fractional
Shares. No fractional shares of Common Stock will be issued in connection with any exercise hereunder, but in lieu of such
fractional shares the Company shall make a cash payment therefor based on the fair market value of the Common Stock on the date
of exercise as reasonably determined in good faith by the Company’s Board of Directors.

 

7.          Compliance
with Securities Act; Disposition of Warrant or Shares of Common Stock.

 

(a)          Compliance
with Securities Act. The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the Shares to be issued
upon exercise hereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant,
or any Shares except under circumstances which will not result in a violation of the Securities Act of 1933, as amended (the “Act”)
or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being acquired are registered under the
Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm
in writing that the Shares so purchased are being acquired for investment and not with a view toward distribution or resale in
violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company. This Warrant
and all Shares issued upon exercise of this Warrant (unless registered under the Act and any applicable state securities laws)
shall be stamped or imprinted with a legend in substantially the following form:

 

“THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT
(i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY
TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL
AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE SECURITIES
WERE ISSUED, DIRECTLY OR INDIRECTLY.”

 

Said legend shall be removed by the Company,
upon the request of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated.
In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of
this Warrant as follows:

 

(1)         The
holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company
sufficient to reach an informed and knowledgeable decision to acquire this Warrant. The holder is acquiring this Warrant for its
own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution”
thereof in violation of the Act.

 

(2)         The
holder understands that this Warrant has not been registered under the Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein.

 

    	-4-

    	 

    

 

(3)         The
holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified
under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The
holder is aware of the provisions of Rule 144, promulgated under the Act.

 

(4)         The
holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under
the Act.

 

(b)          Disposition
of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant
to the exercise of this Warrant prior to registration of such Warrant or Shares, the holder hereof agrees to give written notice
to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel,
or other evidence, if reasonably satisfactory to the Company, to the effect that such offer, sale or other disposition may be effected
without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of
this Warrant or the Shares and indicating whether or not under the Act certificates for this Warrant or the Shares to be sold or
otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance
with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company, as promptly
as practicable but no later than fifteen (15) days after receipt of the written notice, shall notify such holder that such holder
may sell or otherwise dispose of this Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company.
If a determination has been made pursuant to this Section 7(b) that the opinion of counsel for the holder or other evidence
is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such
determination has been made. Notwithstanding the foregoing, this Warrant or such Shares may, as to such federal laws, be offered,
sold or otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been
furnished with such information as the Company may reasonably request to provide a reasonable assurance that the provisions of
Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the Shares thus transferred (except a
transfer pursuant to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to
ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required in order
to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with
such restrictions.

 

(c)          Applicability
of Restrictions. Neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b)
above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Common Stock obtainable upon exercise
thereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a member of the holder if
the holder is a limited liability company, (ii) to a partnership of which the holder is a partner or to a limited liability
company of which the holder is a member, (iii) to any affiliate of the holder if the holder is a corporation, (iv)
notwithstanding the foregoing, to any corporation, company, limited liability company, limited partnership, partnership,
or other person managed or sponsored by Horizon Technology Finance Corporation ("HRZN") or in which HRZN has an interest,
(v) or to a lender to the holder or any of the foregoing; provided, however, in any such transfer, if applicable,
the transferee shall on the Company’s request agree in writing to be bound by the terms of this Warrant as if an original
holder hereof.

 

    	-5-

    	 

    

 

8.          Rights
as Shareholders; Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed
the holder of Common Stock which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained
herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a shareholder of the Company or any
right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to receive
notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and
the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. Notwithstanding the foregoing,
the Company will transmit to the holder of this Warrant such information, documents and reports as are generally distributed to
the holders of any class or series of the securities of the Company concurrently with the distribution thereof to the shareholders;
provided, that any such item which is available on the SEC’s EDGAR system (or successor thereto) or on the Company’s
website need not be furnished in physical form.

 

9.          Registration
Rights. The Shares issuable hereunder initially shall be exempt from registration under the Securities Act. Following the Date
of Grant, and in any case within ninety (90) days thereof, Company shall promptly prepare, file and use its reasonable efforts
to cause to become effective as soon as practicable thereafter, a registration statement on Form S-1 or such other form as
may be appropriate to be filed with the SEC by Company under the Act (together with any amendments or supplements thereto, whether
prior to or after the effective date thereof, the “Registration Statement”) covering the public resale in the United
States of the Shares to be issued pursuant to this Warrant, and Company shall use its reasonable efforts to keep the Registration
Statement continuously effective during the Term. Any such registration shall be subject to the customary terms and conditions
used in connection with resale prospectuses. Company’s obligations under this Section are contingent upon Holder providing
promptly all information concerning such Holder and its proposed plan of distribution as Company may reasonably request in connection
with any of the foregoing. Company may by written notice to the Holder immediately suspend the use of any resale prospectus for
a period not to exceed sixty consecutive days in any one instance and for a period not to exceed one hundred twenty calendar days
in any twelve-month period (each, a “Suspension Period”) at any time that (i) Company becomes engaged in a business
activity or negotiation or any other event has occurred or is anticipated which is not disclosed in that prospectus which Company
reasonably believes should be disclosed therein under applicable law and which Company desires to keep confidential for business
purposes or (ii) Company determines that a particular disclosure so determined to be required to be disclosed therein be premature
or would adversely affect Company or its business or prospects. Company will use its commercially reasonable efforts to ensure
that the use of the Registration Statement may be resumed as soon as practicable. Company shall bear all costs and expenses associated
with the registration of the Shares as specified in this Section and the preparation and filing of the Registration Statement,
including, without limitation, all printing expenses, legal fees and disbursement of Company’s outside counsel, commissions,
NASDAQ and blue sky registration filing fees and transfer agents’ and registrars’ fees, but not including underwriting
commissions or similar charges and legal fees and disbursements of counsel to Holder. The Company shall keep the Registration Statement
effective until the earlier of (a) all Shares have been disposed of in accordance with such effective Registration Statement, (b)
all Shares have been previously sold in accordance with Rule 144, or (c) all Shares are eligible for resale without volume or manner-of-sale
restrictions and without current public information pursuant to Rule 144 (assuming that this Warrant is exercised via the “net
issuance” right provided for in Section 10.2 hereof), as reasonably determined by the Company, upon the advice of counsel
to the Company.

 

    	-6-

    	 

    

 

10.        Additional
Rights.

 

10.1      Acquisition
Transactions. The Company shall provide the holder of this Warrant with at least twenty (20) days’ written notice prior
to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof):
(i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s property
or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of
the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more
than 50% of the voting power of the Company is disposed of.

 

10.2      Right
to Convert Warrant into Stock: Net Issuance.

 

(a)          Right
to Convert. In addition to and without limiting the rights of the holder under the terms of this Warrant, the holder shall
have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Common Stock
as provided in this Section 10.2 at any time or from time to time during the term of this Warrant. Upon exercise of the Conversion
Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company
shall deliver to the holder (without payment by the holder of any exercise price or any cash or other consideration) that number
of shares of fully paid and nonassessable Common Stock as is determined according to the following formula:

 

	X =	B - A  
	 	   Y

 

	Where:	  X  =	the number of shares of Common Stock that shall  be issued to holder
	 	 	 
	 	  Y  =	the fair market value of one share of Common Stock
	 	 	 
	 	  A  =	the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of Converted Warrant Shares multiplied by the Warrant Price)
	 	 	 
	 	  B  =	the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair market value of one Converted Warrant Share)

 

No fractional shares shall be issuable upon
exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula
is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting
fractional share on the Conversion Date (as hereinafter defined). For purposes of Section 10 of this Warrant, shares issued
pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant.

 

    	-7-

    	 

    

 

 

(b)          Method
of Exercise. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of
the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying
that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which
are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion
Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement,
or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof, may
be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant
to a Registration Statement under the Act (a “Public Offering”). Certificates for the shares issuable upon exercise
of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant,
shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days following the Conversion
Date.

 

(c)           Determination
of Fair Market Value. For purposes of this Section 10.2, “fair market value” of a share of Common Stock as
of a particular date (the “Determination Date”) shall mean:

 

(i)          If
the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration
Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities
and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect to such
offering.

 

(ii)         If
the Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows:

 

(A)         If
traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices
of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date;

 

(B)         If
traded on the NASDAQ Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to
be the average of the closing prices of the Common Stock over the five trading days immediately prior to the Determination Date;
and

 

(C)         If
there is no public market for the Common Stock, then fair market value shall be determined by mutual agreement of the holder of
this Warrant and the Company.

 

If closing prices or closing bid prices are no longer reported
by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such
securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading day.

 

    	-8-

    	 

    

 

10.3      Exercise
Prior to Expiration.  To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if
the fair market value of one share of the Common Stock is greater than the Warrant Price then in effect, this Warrant shall be
deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration.
For purposes of such automatic exercise, the fair market value of one share of the Common Stock upon such expiration shall be determined
pursuant to Section 10.2(c). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant
to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder
hereof is to receive by reason of such automatic exercise.

 

11.        Representations
and Warranties. The Company represents and warrants to the holder of this Warrant as follows:

 

(a)          This
Warrant has been duly authorized and executed by the Company and is a valid and binding obligation of the Company enforceable in
accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors
and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

 

(b)          The
Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof,
will be validly issued, fully paid and nonassessable and free from preemptive rights.

 

(c)          A
true and correct copy of the Company’s Restated Certificate of Incorporation, as amended through the Date of Grant has been
provided to Holder (the “Charter”). The rights, preferences, privileges and restrictions granted to or imposed upon
the classes and series of the Company’s capital stock and the holders thereof are as set forth in the Charter.

 

(d)          The
execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with
the terms hereof will not be, inconsistent with the Company’s Charter or by-laws, do not and will not contravene any law,
governmental rule or regulation, judgment or order applicable to the Company, and do not and will not conflict with or contravene
any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is
a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing with
or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except
for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the time required thereby.

 

(e)          There
are no actions, suits, audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the
Company in any court or before any governmental commission, board or authority which, if adversely determined, could have a material
adverse effect on the ability of the Company to perform its obligations under this Warrant.

 

(f)          The
number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion
of all outstanding convertible securities and the exercise of all outstanding options and warrants) and including the issuance
of shares of Common Stock and warrants in the concurrent equity offering, does not exceed 267,158,324 shares.

 

    	-9-

    	 

    

 

12.         Modification
and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in
writing signed by the party against which enforcement of the same is sought.

 

13.         Notices.
Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the
Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address
as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant.

 

14.         Binding
Effect on Successors. This Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or
acquisition of all or substantially all of the Company’s assets, and all of the obligations of the Company relating to the
Shares issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this
Warrant and all of the covenants and agreements of the Company shall inure to the benefit of the successors and assigns of the
holder hereof.

 

15.         Lost
Warrants or Stock Certificates. The Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such
loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company (including in the case of a lost
stock certificate, posting of a bond as required by the Company’s transfer agent), or in the case of any such mutilation
upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock
certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 

16.         Descriptive
Headings. The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do not constitute
a part of this Warrant. The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted
this Warrant.

 

17.         Governing
Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the
laws of the State of Delaware.

 

18.         Survival
of Representations, Warranties and Agreements. All representations and warranties of the Company and the holder hereof contained
herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration
of rights hereunder. All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by
their respective terms, they are no longer operative.

 

    	-10-

    	 

    

 

19.         Remedies.
In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof
(in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce
their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a
result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant.

 

20.         No
Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the
holder of this Warrant against impairment.

 

21.         Severability.
The invalidity or unenforceability of any provision of this Warrant in any jurisdiction shall not affect the validity or enforceability
of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and
effect.

 

22.         Recovery
of Litigation Costs. If any legal action or other proceeding is brought for the enforcement of this Warrant, or because of
an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful
or prevailing party or parties shall be entitled to recover reasonable attorneys’ fees and other costs incurred in that action
or proceeding, in addition to any other relief to which it or they may be entitled.

 

23.         Entire
Agreement; Modification. This Warrant constitutes the entire agreement between the parties pertaining to the subject matter
contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether
oral or written, with respect to such subject matter.

 

[Remainder of page intentionally
blank. Signature page follows.]

 

    	-11-

    	 

    

 

The Company has caused this Warrant to be
duly executed and delivered as of the Date of Grant specified above.

 

	 	INTERLEUKIN GENETICS, INC.
	 	 	 
	 	By:	/s/ Kenneth S. Kornman 
	 	Name:	 Kenneth S. Kornman
	 	Title:	CEO

                                                                 

	 	 	 
	 	Address:	135 Beaver Street
	 	 	Lexington, MA 02452

 

Signature Page to Warrant

 

    	 

    	 

    

 

EXHIBIT A-1

 

NOTICE OF EXERCISE

 

To:INTERLEUKIN GENETICS, INC. (the “Company”)

 

1.             The
undersigned hereby:

 

		☐	elects to purchase________ shares of Common Stock of the
Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full,
or

 

		☐	elects to exercise its net issuance rights pursuant to
Section 10.2 of the attached Warrant with respect to________shares of Common Stock.

 

2.            Please
issue a certificate or certificates representing ________ shares in the name of the undersigned or in such other name or names
as are specified below:

 

 

(Name)

  

 

 

 

(Address)

 

3.            The
undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with
a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing
or reselling such shares, all except as in compliance with applicable securities laws.

 

	 	 	 
	 	 	(Signature)
	 	 	 
	 	 	 
	(Date)

	 	 

 

 

 

    	 

    	 

    

 

EXHIBIT A-2

 

NOTICE OF EXERCISE

 

		To:	INTERLEUKIN GENETICS, INC. (the “Company”)

 

1.          Contingent
upon and effective immediately prior to the closing (the “Closing”) of the Company’s public offering contemplated
by the Registration Statement on Form S___, filed________, 20__, the undersigned hereby:

 

 ̈         elects
to purchase________shares of Common Stock of the Company (or such lesser number of shares as may be sold on behalf of the undersigned
at the Closing) pursuant to the terms of the attached Warrant, or

 

 ̈         elects
to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to________shares of Common
Stock.

 

2.           Please
deliver to the custodian for the selling shareholders a stock certificate representing such________shares.

 

3.           The
undersigned has instructed the custodian for the selling shareholders to deliver to the Company $________or, if less, the net proceeds
due the undersigned from the sale of shares in the aforesaid public offering. If such net proceeds are less than the purchase price
for such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing.

 

	 	 	 
	 	 	(Signature)
	 	 	 
	 	 	 
	(Date)Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

by and between

 

Interleukin Genetics, Inc.

 

and

 

The Purchasers Identified on Schedule
I Hereto

 

December 23, 2014

 

    	 

    	 

    

  

Table
of Contents

 

	 	 	Page
	 	 	 
	1.	PURCHASE AND SALE	1
	 	 	 
	 	(a)	Authorization of Shares	1
	 	 	 	 
	 	(b)	Purchase of Shares and Warrants	1
	 	 	 
	2.	CLOSING	1
	 	 	 
	 	(a)	The Closing	1
	 	 	 	 
	 	(b)	Form of Payment	2
	 	 	 	 
	 	(c)	Conditions to the Purchaser’s Obligation to Purchase on the Closing Date	2
	 	 	 	 
	 	(d)	Conditions to the Company’s Obligation to Issue and Sell on the Closing Date	3
	 	 	 
	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	4
	 	 	 
	 	(a)	Organization and Qualification	4
	 	 	 	 
	 	(b)	Subsidiaries	4
	 	 	 	 
	 	(c)	Authorization; Enforcement; Validity	4
	 	 	 	 
	 	(d)	Capitalization	5
	 	 	 	 
	 	(e)	Issuance of Shares	6
	 	 	 	 
	 	(f)	No Conflicts	6
	 	 	 	 
	 	(g)	No Violation or Default	6
	 	 	 	 
	 	(h)	SEC Documents	6
	 	 	 	 
	 	(i)	Financial Statements	7
	 	 	 	 
	 	(j)	No Material Adverse Change	7
	 	 	 	 
	 	(k)	Independent Accountants	7
	 	 	 	 
	 	(l)	Title to Intellectual Property	8
	 	 	 	 
	 	(m)	Licenses and Permits; Compliance with Law	8
	 	 	 	 
	 	(n)	Insurance	8
	 	 	 	 
	 	(o)	Related Party Transactions	9
	 	 	 	 
	 	(p)	Environmental Matters	9
	 	 	 	 
	 	(q)	Tax Matters	9

 

    	-i-

    	 

    

  

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	 	(r)	Employees	10
	 	 	 	 
	 	(s)	Internal Control over Financial Reporting	10
	 	 	 	 
	 	(t)	Disclosure Controls and Procedures	10
	 	 	 	 
	 	(u)	Sarbanes-Oxley Compliance	10
	 	 	 	 
	 	(v)	Absence of Litigation	10
	 	 	 	 
	 	(w)	Investment Company Act	11
	 	 	 	 
	 	(x)	No Market Manipulation	11
	 	 	 	 
	 	(y)	Foreign Corrupt Practices	11
	 	 	 	 
	 	(z)	Brokers	11
	 	 	 	 
	 	(aa)	Regulation	11
	 	 	 
	4.	PURCHASERS’ REPRESENTATIONS AND WARRANTIES	12
	 	 	 
	 	(a)	Transfer or Resale	12
	 	 	 	 
	 	(b)	Investment Purpose	12
	 	 	 	 
	 	(c)	General Solicitation	12
	 	 	 	 
	 	(d)	Information	12
	 	 	 	 
	 	(e)	Reliance on Exemptions	12
	 	 	 	 
	 	(f)	No Governmental Review	13
	 	 	 	 
	 	(g)	Authorization; Enforcement; Validity	13
	 	 	 	 
	 	(h)	No Conflicts	13
	 	 	 
	5.	RESTRICTIONS ON TRANSFER	13
	 	 	 
	 	(a)	Resales	13
	 	 	 	 
	 	(b)	Rule 144	13
	 	 	 	 
	 	(c)	Legends	14
	 	 	 	 
	 	(d)	Legend Removal	15
	 	 	 	 
	6.	BOARD COMPOSITION	15
	 	 	 	 
	 	(a)	Board Composition; Appointment of Director Designees	15
	 	 	 	 
	 	(b)	Nominations of Director Designees	15
	 	 	 	 
	 	(c)	Successor Director Designees	15

 

 

    	-ii-

    	 

    

  

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	 	(d)	Indemnification Agreements	16
	 	 	 	 
	 	(e)	Committees of the Board of Directors	16
	 	 	 	 
	 	(f)	Amendment of this Section 6	16
	 	 	 	 
	 	(g)	Board Observer Rights	16
	 	 	 	 
	7.	OTHER AGREEMENTS AND COVENANTS	17
	 	 	 	 
	 	(a)	National Market Listing	17
	 	 	 	 
	 	(b)	Use of Proceeds	17
	 	 	 	 
	 	(c)	Form D; Blue Sky Filings	17
	 	 	 	 
	 	(d)	Reservation of Shares	17
	 	 	 	 
	 	(e)	Exchange Act Filings	17
	 	 	 	 
	 	(f)	Integration	17
	 	 	 	 
	 	(g)	Expenses	18
	 	 	 	 
	 	(h)	Purchaser/Director Designee Exchange Act Filings	18
	 	 	 
	8.	PUBLIC STATEMENTS	18
	 	 	 
	9.	MISCELLANEOUS	18
	 	 	 
	 	(a)	Governing Law	18
	 	 	 	 
	 	(b)	Entire Agreement	19
	 	 	 	 
	 	(c)	Amendments and Waivers	19
	 	 	 	 
	 	(d)	Notices	19
	 	 	 	 
	 	(e)	No Strict Construction	20
	 	 	 	 
	 	(f)	Further Assurances	20
	 	 	 	 
	 	(g)	Severability	20
	 	 	 	 
	 	(h)	Successors and Assigns	20
	 	 	 	 
	 	(i)	Survival	20
	 	 	 	 
	 	(j)	No Third-Party Beneficiaries	21
	 	 	 	 
	 	(k)	Replacement of Securities	21
	 	 	 	 
	 	(l)	Independent Nature of Purchasers’ Obligations and Rights	21
	 	 	 	 
	 	(m)	Business Day	21

 

    	-iii-

    	 

    

  

Table
of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	(n)	Headings	21
	 	 	 	 
	 	(o)	Execution	21

 

SCHEDULES

Schedule I – List of Purchasers

 

EXHIBITS

Exhibit A – Form of Warrant

 

Exhibit B – Registration Rights Agreement

 

    	-iv-

    	 

    

  

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase Agreement (this
“Agreement”) dated as of December 23, 2014 is made by and between Interleukin Genetics, Inc., a Delaware corporation,
(the “Company”), and each purchaser identified on Schedule I hereto (each a “Purchaser”),
and together, the “Purchasers”). 

 

RECITALS

 

In accordance with the terms and conditions
of this Agreement and pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities
Act”), the Company has agreed to issue and sell, and each Purchaser has agreed, severally and not jointly, to purchase
a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and
a warrant to purchase a number of shares of Common Stock (the “Warrant”, and together with all such warrants
being issued to Purchasers under this Agreement, the “Warrants”), each as set forth opposite such Purchaser’s
name on Schedule I to this Agreement.

 

NOW THEREFORE, in consideration of the promises
and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Purchaser hereby agree as follows:

 

1.          PURCHASE
AND SALE

 

(a)     Authorization
of Shares. The Company has authorized (i) the sale and issuance to the Purchasers of the shares of Common Stock, (ii)
the sale and issuance to the Purchasers of the Warrants, and (iii) the issuance of shares of Common Stock to be issued upon
exercise of the Warrants (the “Warrant Shares”).

 

(b)      Purchase
of Shares and Warrants. At the Closing (as defined below), the Company shall issue and sell to each Purchaser, and each Purchaser
shall, severally and not jointly, purchase from the Company, upon the terms and subject to the conditions set forth in this Agreement,
(i) the number of shares of Common Stock set forth opposite such Purchaser’s name on Schedule I to this Agreement
(the “Shares”) and (ii) a Warrant to purchase the number of shares of Common Stock set forth opposite such
Purchaser’s name on Schedule I to this Agreement, for an aggregate purchase price as set forth opposite such Purchaser’s
name on Schedule I to this Agreement (the “Purchase Price”), based on a purchase price per Share of
$0.1003 (the “Per Share Purchase Price”).

 

2.          CLOSING

 

(a)      The
Closing. The date and time of the Closing of the purchase and sale of the Shares and the Warrants (the “Closing”)
shall occur on December 23, 2014 at 12:00 p.m. Boston time, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
One Financial Center, Boston, Massachusetts, 02111 (subject to the satisfaction or waiver of the conditions set forth in Subsections
(c) and (d) of this Section 2), or at such other location, date and time as may be agreed upon between the Company and the Purchasers
(the “Closing Date”).

 

    	 

    	 

    

  

(b)      Form
of Payment. On the Closing Date, each Purchaser shall pay the Company the Purchase Price for the Shares and the Warrant to
be issued and sold to such Purchaser on such Closing Date, by wire transfer of immediately available funds in accordance with the
Company’s written wire instructions previously provided to the Purchasers, and the Company shall deliver to each Purchaser
the original certificate or certificates representing the Shares and the original Warrant, duly executed on behalf of the Company
and registered in the name of such Purchaser.

 

(c)      Conditions
to the Purchaser’s Obligation to Purchase on the Closing Date. Each Purchaser’s obligation to purchase the Shares
and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following conditions,
provided that these conditions are for the Purchaser’s sole benefit and may be waived by such Purchaser at any time in its
sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by the Company;

 

		(ii)	the Company shall have entered into an agreement with Horizon
Technology Finance Management LLC and/or its assignees and/or other lenders with respect to a $5,000,000 venture loan (the “Venture
Loan Agreement”);

 

		(iii)	evidence of irrevocable instructions from the Company to
the transfer agent for the Common Stock with respect to the issuance and delivery of one or more certificates representing the
Shares;

 

		(iv)	receipt of the Warrant in the form attached as Exhibit
A;

 

		(v)	all actions required by the Board of Directors of the Company
(the “Board”) to effect the provisions of Section 6 of this Agreement with respect to the composition of the
Board following the Closing shall have been taken;

 

		(vi)	all consents, approvals and waivers required for the consummation
of the transactions contemplated hereby shall have been obtained;

 

		(vii)	the Company shall have delivered to the Purchasers a Compliance
Certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the effect that the conditions
specified in subsections (vi), (ix), and (x) of this Section 2(c) have been satisfied;

 

		(viii)	the Company shall have delivered to the Purchasers a certificate
of its Secretary certifying as to (A) the resolutions of the Board approving this Agreement and the transactions contemplated
hereby, including the actions required by the Company pursuant to this Section 2(c); and (B) good standing certificates
(including tax good standing) with respect to the Company from the applicable authority(ies) in Delaware and any other jurisdiction
in which the Company is qualified to do business dated a recent date before the Closing;

 

    	-2-

    	 

    

  

		(ix)	the representations and warranties of the Company in this
Agreement shall be true, correct and complete as of the Closing Date (except for representations and warranties that speak as
of a specific date, which shall be true, correct and complete as of such date) and the Company shall have performed, satisfied
and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Company at or prior to the Closing;

 

		(x)	no temporary restraining order, preliminary or permanent
injunction or other order or decree, and no other legal restraint or prohibition, shall exist which questions the validity of
this Agreement or the right of the Company or any Purchaser, as the case may be, to enter into this Agreement or prevents or could
reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, nor shall any litigation
or court or administrative proceeding have been commenced or threatened with respect to the foregoing;

 

		(xi)	the Company shall have executed and delivered the Registration
Rights Agreement in substantially the form attached as Exhibit B (the “Registration Rights Agreement”);

 

		(xii)	delivery of a legal opinion of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, Company counsel, in form and substance reasonably satisfactory to the Purchasers; and

 

		(xiii)	receipt of such other information, certificates and documents
as the Purchasers may reasonably request.

 

(d)      Conditions
to the Company’s Obligation to Issue and Sell on the Closing Date. The Company’s obligation to issue and sell the
Shares and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each of the following
conditions, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time
in its sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by each Purchaser;

 

		(ii)	receipt of the Purchase Price from each Purchaser;

 

		(iii)	the representations and warranties of each Purchaser in
this Agreement shall be true, correct and complete as of the date of this Agreement and as of the Closing Date (except for representations
and warranties that speak as of a specific date, which shall be true, correct and complete as of such date) and each Purchaser
shall have performed, satisfied and complied with in all material respects the covenants, agreements and conditions of such Purchaser
to be performed, satisfied or complied with by it under this Agreement at or prior to the Closing Date; and

 

    	-3-

    	 

    

  

		(iv)	no temporary restraining order, preliminary or permanent
injunction or other order or decree, and no other legal restraint or prohibition shall exist which questions the validity of this
Agreement or the right of the Company or any Purchaser, as the case may be, to enter into this Agreement or prevents or could
reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, nor shall any litigation
or court or administrative proceeding have been commenced or threatened with respect to the foregoing.

 

3.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to each
Purchaser, subject to such exceptions as are set forth in the SEC Documents (as defined below) (other than (x) those sections of
the SEC Documents entitled or captioned “Risk Factors,” (y) any disclosure of risks included in any forward-looking
statements disclaimer or other statements that are similarly non-specific and are predictive or forward looking in nature and (z)
specific disclosures contained in those documents which are filed as exhibits to the SEC Documents), provided that the relevance
of such exceptions to the representations and warranties is reasonably apparent, as follows:

 

(a)      Organization
and Qualification. The Company is a corporation, duly organized, validly existing and in good standing under the laws of the
State of Delaware, and has the requisite corporate power and authority to own its properties and to carry on its business as now
being conducted and as described in the SEC Documents. Copies of the Company’s Restated Certificate of Incorporation (the
“Charter”) and Amended and Restated Bylaws of the Company, as amended (the “Bylaws”), and
in each case, all amendments thereto, have been filed as exhibits to the Company’s SEC Documents and have not been further
modified, and except as otherwise may be required by the transactions contemplated hereby, the Company has no present intention
to modify the Charter and Bylaws. The Company is duly qualified as a foreign corporation to do business, and is in good standing,
in every jurisdiction in which its ownership of property or the nature of the business conducted and proposed to be conducted by
it makes such qualification necessary, except where the failure to be so qualified or in good standing would not, individually
or in the aggregate, have or reasonably be expected to result in a material adverse effect on (i) the condition (financial or otherwise),
prospects, earnings, assets, results of operations, business or properties of the Company, whether or not arising from transactions
in the ordinary course of business or (ii) the ability of the Company to consummate the transactions contemplated by this Agreement
(“Material Adverse Effect”).

 

(b)      Subsidiaries.
The Company has no subsidiaries.

 

(c)      Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, the Registration Rights Agreement, the Venture Loan Agreement and each of the other agreements entered into
by the parties hereto in connection with transactions contemplated by this Agreement (collectively, the “Transaction Documents”)
and to issue the Shares and the Warrants in accordance with the terms hereof and thereof. The execution and delivery of the Transaction
Documents by the Company and the consummation and performance by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Shares, Warrants and the Warrant Shares (collectively, the “Securities”),
have been duly authorized by all requisite corporate action. The Transaction Documents have been duly executed and delivered by
the Company. The Transaction Documents constitute the valid and binding obligations of the Company enforceable against the Company
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies.

 

    	-4-

    	 

    

  

(d)      Capitalization.
As of the date of this Agreement, the authorized capital stock of the Company consists of (i) 300,000,000 shares of Common Stock
and (ii) 6,000,000 shares of undesignated preferred stock, $0.001 par value per share. As of the date of this Agreement and prior
to the issuance of the Shares and Warrants under this Agreement, (i) 122,583,642 shares of Common Stock are issued and outstanding;
(ii) 4,523,900 shares of Common Stock are duly reserved for future issuance pursuant to outstanding stock options; (iii) 37,269,126
shares of Common Stock are duly reserved for future issuance pursuant to outstanding warrants; (iv) 5,954,825 shares of Common
Stock are duly reserved for future issuance pursuant to the Company’s stock plans; and (v)  503,952 shares of Common
Stock are duly reserved for future issuance pursuant to the Company’s employee stock purchase plan. All of the issued shares
of capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable, and have been
issued in compliance with federal and state securities laws. Except as set forth above, (i) no shares of the Company’s capital
stock are subject to preemptive rights or any other similar rights or any liens or encumbrances; (ii) there are no outstanding
options, warrants, rights to subscribe to, calls or commitments relating to, or securities or rights convertible into, any shares
of capital stock of the Company, or contracts, commitments, understandings or arrangements by which the Company is or may become
bound to issue additional shares of capital stock of the Company or options, warrants, rights to subscribe to, calls or commitments
relating to, or securities or rights convertible into, any shares of capital stock of the Company. The Company has no knowledge
of any voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among
any of the security holders of the Company relating to the securities of the Company held by them. Other than (i) pursuant to the
Registration Rights Agreement, (ii) with respect to the shares of Common Stock issuable upon exercise of the warrant to be issued
pursuant to the Venture Loan Agreement, and (iii) except as set forth in that certain Registration Rights Agreement, dated May
17, 2013, between the Company and the purchasers signatory thereto, the Company has not granted any person the right to require
the Company to register any securities of the Company under the Securities Act, whether on a demand basis or in connection with
the registration of securities of the Company for its own account or for the account of any other person.

 

    	-5-

    	 

    

  

(e)      Issuance
of Shares. The Shares and the Warrant Shares have been duly and validly reserved for issuance. The Shares and the Warrant Shares
are duly authorized and, upon issuance in accordance with the terms hereof and the Warrants, will be (A) validly issued, fully
paid and non-assessable and (B) free from all taxes, liens and charges in the United States of America with respect to the issuance
thereof, other than any liens or encumbrances created by or imposed by the Purchaser, and not subject to preemptive, registration,
right of first refusal or other similar rights of stockholders of the Company. Except for the filing of any notice prior or subsequent
to the Closing that may be required under applicable state and/or federal securities laws (or comparable laws of any other jurisdiction),
no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department,
commission, board, bureau, agency, instrumentality or other third party, is or will be necessary for, or in connection with, the
execution and delivery by the Company of this Agreement, for the offer, issue, sale, execution or delivery of the Shares and Warrants,
or for the performance by the Company of its obligations under this Agreement. The Company has reserved from its duly authorized
capital stock the Shares and the Warrant Shares.

 

(f)      No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby do not and will not (i) result in a breach or violation of the Company’s
Charter or Bylaws; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become
a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or incremental, additional
or varied rights under, any agreement, indenture, or other instrument, obligation or understanding to which the Company is a party;
(iii) result in a violation of any statute, law, rule, regulation, order, judgment or decree (including federal and state securities
laws) applicable to the Company; or (iv) result in the imposition of a mortgage, pledge, security interest, encumbrance, charge
or other lien on any asset of the Company.

 

(g)      No
Violation or Default. The Company is not (i) in violation of its Charter or Bylaws; (ii) in default (or subject to an event
which with notice or lapse of time or both would become a default) under any agreement, indenture or instrument to which the Company
is a party; or (iii) in violation of any law, rule, regulation, order, judgment or decree applicable to the Company; except for
such violations or defaults, as described in clauses (ii) or (iii) of this sentence as would not, individually or in the aggregate,
have or result in a Material Adverse Effect.

 

(h)      SEC
Documents. The Company has filed all reports, schedules, forms, statements, exhibits (including certifications of the Company’s
principal executive and financial officers pursuant to Section 302 and 906 of Sarbanes-Oxley (as defined below)) and other documents
required to be filed by it with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the reporting
requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since January 1, 2013
(all of the foregoing filed prior to or on the date hereof, or prior to the Closing Date, and all exhibits included therein and
financial statements and schedules thereto and documents incorporated by reference therein being referred to in this Agreement
as the “SEC Documents”). As of the date of filing of each such SEC Document, such SEC Document, as it may have
been subsequently amended by filings made by the Company with the SEC prior to the date hereof, complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to such SEC
Document. None of the SEC Documents, as of the date filed and as they may have been subsequently amended by filings made by the
Company with the SEC prior to the date hereof, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading.

 

    	-6-

    	 

    

  

(i)      Financial
Statements. The financial statements and the related notes thereto of the Company included or incorporated by reference in
the SEC Documents comply in all material respects with the applicable requirements of the Exchange Act and present fairly and accurately
in all material respects the financial position of the Company as of the dates indicated and the results of operations and the
changes in cash flows for the periods specified. Such financial statements have been prepared in conformity with United States
generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods covered
thereby, except as specifically stated therein, and the supporting schedules included or incorporated by reference in the SEC Documents
present fairly the information required to be stated therein. The Company does not have any material liability or obligation of
any nature, whether or not accrued, contingent or otherwise that would be required by GAAP to be disclosed on a balance sheet of
the Company or in the notes thereto. The Company has not created any entities or entered into any transactions or created any liabilities
or obligations of any nature, whether or not accrued, contingent or otherwise, for the purpose of avoiding disclosure required
by GAAP.

 

(j)      No
Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated by
reference in the SEC Documents, except as disclosed in the SEC Documents and as contemplated by this Agreement and the Venture
Loan Agreement, (i) there has not been any change in the capital stock (other than pursuant to the Company's stock plans pursuant
to the Company's existing employee stock purchase plan (any such issuances, whenever issued or granted, being collectively “Employee
Equity Transactions”), pursuant to the conversion or exercise of outstanding securities that are convertible into or
exercisable for Common Stock, or pursuant to publicly disclosed equity or debt financings) or long-term debt of the Company, or
any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock;
(ii) the Company has not entered into any transaction or agreement that is material to the Company taken as a whole or incurred
any liability or obligation, direct or contingent, that is material to the Company and, except as contemplated by this agreement,
has not made any material change or amendment to a material contract or arrangement by which the Company or any of its assets or
properties is bound or subject; (iii) the Company has not sustained any material loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority; and (iv) there has not been the occurrence
of any Material Adverse Effect.

 

(k)      Independent
Accountants. Grant Thornton LLP, who have certified certain financial statements of the Company, have advised the Company that
they are, and to the Company’s knowledge they are, independent registered public accountants with respect to the Company
as required by the Securities Act. Except as pre-approved in accordance with the requirements set forth in Section 10A of the Exchange
Act, to the Company’s knowledge, Grant Thornton LLP has not engaged in any “prohibited activities” (as defined
in Section 10A of the Exchange Act) on behalf of the Company.

 

    	-7-

    	 

    

  

(l)      Title
to Intellectual Property. The Company owns or possesses adequate rights to use all patents, patent applications, trademarks,
service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, know-how and
all other intellectual property rights (including trade secrets and other unpatented or unpatentable proprietary or confidential
compounds, genes, information, systems or procedures) (collectively, the “Intellectual Property”), used in or
necessary for the conduct of the Company’s business as now, or as contemplated to be, conducted. Except as set forth in the
SEC Documents, (i) there are no rights of third parties to any such Intellectual Property except through licensing or cross-licensing
agreements; (ii) to the Company’s knowledge, there is no infringement by third parties of any Intellectual Property
to which the Company can assert a claim of infringement; (iii) there is no pending or, to the Company’s knowledge, threatened
action, suit, proceeding or claim by others challenging the Company’s ownership of or licensing rights in or to any such
Intellectual Property; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any such Intellectual Property, other than ordinary patent, trademark,
service mark and copyright prosecution disclosed in the SEC Documents; (v) there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any Intellectual
Property of others, and the Company is unaware of any reasonable basis for any such claim; (vi) the Company has not been and
will not be required to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to
their employment by the Company; (vii) the Company has taken all steps required to perfect its ownership of and interest in
its Intellectual Property; and (viii) the Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of its Intellectual Property.

 

(m)      Licenses
and Permits; Compliance with Law. The Company possesses all licenses, certificates, permits and other authorizations issued
by, and has made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities, that are necessary for the ownership or lease of its properties and assets or the conduct of its business as conducted
or as contemplated to be conducted. The Company has not received notice of any revocation or modification of any such license,
certificate, permit or authorization, or of any proceeding relating to any such revocation or modification, or has any reason to
believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. The Company has
complied in all material respects with and is not in default or violation in any material respect of, and is not, to the Company’s
knowledge, under investigation with respect to or has not been, to the knowledge of the Company, threatened to be charged with
or given notice of any violation of, any applicable federal, state, local or foreign law, statute, ordinance, license, rule, regulation,
policy or guideline, order, demand, writ, injunction, decree or judgment of any federal, state, local or foreign governmental or
regulatory authority. Except for statutory or regulatory restrictions of general application, no federal, state, local or foreign
governmental or regulatory authority has placed any material restriction on the business or properties of the Company.

 

(n)      Insurance.
The Company maintains insurance of the types and in the amounts that the Company reasonably believes are adequate for its businesses
and consistent with insurance coverage maintained by similar companies in similar businesses, including, but not limited to, insurance
covering real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism, insurance
covering the acts and omissions of directors and officers, and insurance covering all other risks customarily insured against by
similarly situated companies, all of which insurance is in full force and effect. The Company has not received any written notice
that the Company will not be able to renew its existing insurance coverage as and when such coverage expires.

 

    	-8-

    	 

    

  

(o)      Related
Party Transactions. Except as contemplated by this Agreement, none of the officers or directors of the Company and, to the
knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000
other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) for other employee benefits, including stock option agreements under any stock option plan of the
Company.

 

(p)      Environmental
Matters. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations relating to the
use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment
which are applicable to their businesses. To the Company’s knowledge, there has been no storage, generation, transportation,
handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances
by, due to, or caused by the Company (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company
is or may be liable) upon any of the property now or previously owned or leased by the Company, or upon any other property, in
violation of any statute or any ordinance, rule, regulation, order, judgment, decree or permit or which would, under any statute
or any ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability.
There has been no disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding
such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.

 

(q)      Tax
Matters. The Company (i) has timely filed all necessary federal, state, local and foreign income and franchise tax returns
or has requested extensions thereof, (ii) has paid all federal state, local and foreign taxes due and payable for which it is liable,
except for any such taxes currently being contested in good faith, and (iii) does not have any tax deficiency or claims outstanding
or assessed or, to the best of the Company’s knowledge, proposed against it. All material taxes and other assessments and
levies that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the
proper government entity or third party when due. There are no tax liens or claims pending or, to the Company’s knowledge,
threatened against the Company or any of its respective assets or property. Except as set forth in the SEC Documents, there are
no outstanding tax sharing agreements or other such arrangements between the Company and any other Person.

 

    	-9-

    	 

    

  

(r)      Employees.
All current and former employees of the Company have executed and delivered a confidential information and inventions assignment
agreement (a “CIIA”) to the Company. All current and former consultants of the Company that had access to confidential
or proprietary information of the Company have executed and delivered a CIIA to the Company or other form of written contract or
agreement with the Company that requires such consultants to maintain the confidentiality of such information and assigns to the
Company all rights to any inventions, improvements, discoveries or information relating to the business of the Company. The Company
is not aware that any executive officer of the Company has plans to terminate his or her employment relationship with the Company.
The Company has complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective
bargaining, workers’ compensation insurance and the payment of social security and other taxes. None of the employees of
the Company is represented by any labor union, and there is no labor strike or other labor trouble pending or, to the Company’s
knowledge, threatened with respect to the Company. To the Company’s knowledge, no employee of the Company is obligated under
any contract or subject to any judgment, decree or administrative order that would conflict or interfere with (i) the performance
of the employee’s duties as an employee, director or officer of the Company, or (ii) the Company’s business as conducted
or proposed to be conducted.

 

(s)      Internal
Control over Financial Reporting. The Company maintains a system of internal control over financial reporting (as such is defined
in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company’s
principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.
The Company does not have any material weaknesses in its internal control over financial reporting. Since the date of the latest
audited financial statements included in the SEC Documents, there has been no change in the Company’s internal control over
financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control
over financial reporting.

 

(t)      Disclosure
Controls and Procedures. The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e)
of the Exchange Act) that comply with the requirements of the Exchange Act. Such disclosure controls and procedures have been designed
to ensure that material information relating to the Company is accumulated and communicated to the Company’s management,
including the Company’s principal executive officer and principal financial officer, by others within those entities.

 

(u)      Sarbanes-Oxley
Compliance. The Company and the Company’s directors and officers, in their capacities as such, are in compliance with
any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (“Sarbanes-Oxley”),
including Section 402 related to loans and Sections 302 and 906 related to certifications, and neither the Company nor any of its
officers has received notice from any governmental entity questioning or challenging the accuracy, completeness, content, form
or manner of filing or submission of such certifications. The Company has no reasonable basis to believe that it will not continue
to be in compliance with Sarbanes-Oxley as in effect on the Closing Date (including, without limitation, the requirements of Section
404 thereof).

 

(v)         Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened in writing against the Company
which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or the Securities or
(ii) would reasonably be expected to result in a Material Adverse Effect.

 

    	-10-

    	 

    

  

(w)      Investment
Company Act. The Company is not, nor, after giving effect to the sale of the Shares and the Warrants and the application of
the proceeds therefrom, will it become, an “investment company” within the meaning of the Investment Company Act of
1940, as amended, and the rules and regulations of the SEC thereunder.

 

(x)      No
Market Manipulation. Neither the Company nor, to the knowledge of the Company, any of the Company’s directors, officers,
employees, agents or controlling persons have taken, directly or indirectly, any action designed, or that might reasonably be expected,
to cause or result in, under the Securities Act or otherwise, or that has constituted, stabilization or manipulation of the price
of the Common Stock.

 

(y)      Foreign
Corrupt Practices. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee or other
person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company, (i) directly or indirectly,
used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity;
(ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
(iii) violated or is in violation of in any material respect any provision of the U.S. Foreign Corrupt Practices Act of 1977, as
amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign
or domestic government official or employee.

 

(z)      Brokers.
Except pursuant to the agreement with BTIG, LLC (the “Placement Agent”), neither the Company nor any of the
Company's officers, directors, employees or stockholders has employed or engaged any broker or finder in connection with the transactions
contemplated by this Agreement and no other fee or other compensation is or will be due and owing to any broker, finder, underwriter,
placement agent or similar person in connection with the transactions contemplated by this Agreement.

 

(aa)         Regulation.
Assuming the accuracy of the representations and warranties made by the Purchasers in Section 4 of this Agreement, the offer, issuance,
sale and delivery of the Securities are or will be exempt from the registration requirements of the Securities Act and the qualification
or registration provisions of applicable state securities laws. Neither the Company nor its authorized agents have taken or will
take any action that would cause the loss of such exemption. Neither the Company nor any person acting on its behalf has conducted
any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or
sale of any of the Securities. Neither the Company nor any of its affiliates, nor any person acting on its or their behalf has,
directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would adversely affect reliance by the Company on Section 4(2) of the Securities Act for the exemption from registration
for the contemplated transactions under this Agreement or would require registration of the Shares or the Common Shares under the
Securities Act.

 

    	-11-

    	 

    

  

4.          PURCHASERS’
REPRESENTATIONS AND WARRANTIES

 

Each Purchaser, for itself and for no other
Purchaser, hereby represents and warrants to the Company as follows:

 

(a)      Transfer
or Resale. The Purchaser understands that the Securities have not been registered under the Securities Act or any state securities
laws, and may not be offered for sale, sold, assigned or transferred without registration under the Securities Act or an exemption
therefrom and that, in the absence of an effective registration statement under the Securities Act, such Securities may only be
sold under certain circumstances as set forth in the Securities Act.

 

(b)      Investment
Purpose. The Purchaser is acquiring the Securities for its own account for investment only and not with a view towards, or
for resale in connection with, the public sale or distribution thereof. The Purchaser does not have any agreement or understanding,
directly or indirectly, with any person to distribute any of the Securities.

 

(c)      General
Solicitation. The Purchaser was contacted regarding the sale of the Securities by an authorized representative of the Company
or the Placement Agent with whom the Purchaser has a prior substantial pre-existing relationship and the Purchaser is not purchasing
the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any
newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation
or general advertisement.

 

(d)      Information.
The Purchaser (directly or through its advisors, if any) (i) has been furnished with or has had full access to all of the publicly
available information that it considers necessary or appropriate for deciding whether to purchase the Securities, (ii) has had
an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the
Securities, (iii) can bear the economic risk of a total loss of its investment in the Securities and (iv) has such knowledge and
experience in business and financial matters so as to enable it to understand the risks of and form an investment decision with
respect to its investment in the Securities. The Purchaser has received no representation or warranties from the Company, its employees,
agents (including the Placement Agent), or attorneys in making this investment decision other than as set forth in the Transaction
Documents.

 

(e)      Reliance
on Exemptions. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each
date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)
under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities
Act. The Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions from the
registration requirements of the Securities Act and that the Company is relying upon the truth and accuracy of, and the Purchaser’s
compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth in
this Agreement in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities.

 

    	-12-

    	 

    

  

(f)      No
Governmental Review. The Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)      Authorization;
Enforcement; Validity. The Purchaser is an entity duly organized and validly existing under the laws of the jurisdiction of
its organization with full right, corporate or limited partnership power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution, delivery and performance by
the Purchaser of the transactions contemplated by this Agreement has been duly authorized by all necessary corporate or limited
partnership action on the part of the Purchaser and any other governmental action with respect to the Purchaser.  This Agreement
has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with terms hereof, will constitute the
valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

(h)      No
Conflicts. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by the Purchaser
of the transactions contemplated hereby do not and will not (i) result in a violation of the Purchaser’s charter, bylaws,
or other similar organizational documents; (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under any agreement, indenture or other instrument, obligation or understanding to which
the Purchaser is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to
the Purchaser, except for such conflicts, defaults and violations as described in clauses (ii) or (iii) of this sentence as would
not, individually or in the aggregate, have or result in a material adverse effect on the Purchaser.

 

5.           RESTRICTIONS
ON TRANSFER

 

(a)      Resales.
Each Purchaser agrees that the Securities may only be sold or transferred (i) pursuant to an effective registration statement under
the Securities Act (including the Registration Statement (as defined in the Registration Rights Agreement)), or (ii) pursuant to
an exemption from registration under the Securities Act.

 

(b)      Rule
144. Each Purchaser is aware of Rule 144 promulgated by the SEC pursuant to the Securities Act (as such rule may be amended
or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same
purpose and effect as such rule, “Rule 144”) and the restrictions imposed thereby and further understands and
agrees that so long as such Purchaser beneficially owns 10% or more of the Company’s then outstanding securities or has a
designee selected by the Purchaser serving on the Board, the Company will deem the Purchaser to be an “affiliate” as
defined in Rule 144(a)(1) and any transfers of the Securities by the Purchaser shall be subject to the limitations applicable to
affiliates set forth in the Securities Act and the rules promulgated thereunder, including without limitation Rule 144.

 

    	-13-

    	 

    

  

(c)      Legends.
Each Purchaser agrees to the imprinting, so long as is required by this Section 5, of a legend on any of the Securities in substantially
the following form:

 

“THIS SECURITY HAS NOT
BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE
OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL
BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED
BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a)
UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

The Company acknowledges and agrees that a Purchaser may from
time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some
or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under
the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement and, if
required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or
secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the
Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required
prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately
amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.

 

    	-14-

    	 

    

  

(d)      Legend
Removal. The Company shall cause its counsel to promptly issue a legal opinion to the transfer agent for the Common Stock with
respect to removal of the legend set forth in Section 5(c) above, (i) following any sale of such Shares or Warrant Shares pursuant
to an effective registration statement, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144, or (iii)
when such Shares or Warrant Shares may be sold under Rule 144, without the requirement for the Company to be in compliance with
the current public information required under Rule 144 as to such Shares and Warrant Shares and without volume or manner-of-sale
restrictions.

 

6.          BOARD
COMPOSITION

 

(a)      Board
Composition; Appointment of Director Designees. The Board shall take all actions necessary such that the Board shall consist
of seven (7) members and shall be composed as follows:

 

(i)          the
Class I directors with a term ending at the 2016 annual meeting of stockholders shall consist of one independent director (currently
William C. Mills III) and one director designated by Pyxis Innovations Inc. (currently Joseph M. Landstra) (a “Pyxis Designee”);

 

(ii)         the
Class II directors with a term ending at the 2017 annual meeting of stockholders shall consist of the Company’s Chief Executive
Officer and one director designated by Bay City Capital Fund V, L.P. (currently Dayton Misfeldt) (a “BCC Designee”);
and

 

(iii)        the
Class III directors with a term ending at the 2015 annual meeting of stockholders shall consist of one director designated by Pyxis
Innovations Inc. (currently Roger C. Colman) (a “Pyxis Designee”), one independent director (currently James
Weaver), and one director designated by Bay City Capital Fund V, L.P. (currently Lionel Carnot) (a “BCC Designee”).

 

The Pyxis Designees and the BCC Designees, shall be collectively
referred to herein as the “Director Designees.” Each of the shareholders entitled to designate a director hereunder
is referred to herein as a “Designor.” The rights provided under this Section 6 are the exclusive rights of
each such Designor and are not transferable.

 

(b)      Nominations
of Director Designees. For so long as a Designor’s ownership of the outstanding Common Stock of the Company is at least
five percent (5%), any Director Designee (including any successor pursuant to Subsection 6(c) below) designated by such Designor
shall be nominated by the Board of Directors (or a committee thereof) for election at the annual meeting of stockholders at which
such Director Designee’s term will expire. At least ninety (90) days prior to any such annual meeting at or by which directors
are to be elected, such Designor shall notify the Company in writing of the Director Designee to be nominated for election as a
director. The Company shall disclose in its proxy the nominated Director Designee(s). In the absence of any such notification,
it shall be presumed that the Designor’s then incumbent Director Designee(s) has been designated.

 

(c)      Successor
Director Designees. If a Director Designee shall cease to serve as a director for any reason, the Designor of such Director
Designee shall notify the Company in writing of the individual to replace such Director Designee, and the Company’s Board
of Directors shall appoint and elect such replacement director to serve out the remaining term of the existing director.

 

    	-15-

    	 

    

  

(d)      Indemnification
Agreements. The Company shall enter into an Indemnification Agreement with each successor Director Designee prior to the commencement
of his or her service on the Board.

 

(e)      Committees
of the Board of Directors. For so long as the Designor of the BCC Designees has the right to designate Director Designees and
provided that such individuals meet the requirements imposed by the SEC or any exchange upon which the Common Stock may be traded
for membership on such committees, the Board shall appoint a BCC Designee to the Audit Committee, the Compensation Committee and
the Nominating and Governance Committee. For so long as the Designor of the Pyxis Designees has the right to designate Director
Designees and provided that such individual meets the requirements imposed by the SEC or any exchange upon which the Common Stock
may be traded for membership on such committee, the Board shall appoint a Pyxis Designee to the Audit Committee.

 

(f)      Amendment
of this Section 6. For so long as Pyxis Innovations Inc. has the right to designate a Pyxis Designee, no provision of this
Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment shall be
binding on all Purchasers) and Pyxis Innovations Inc. or, in the case of a waiver, by the party against whom enforcement of any
such waived provision is sought. For so long as Bay City Capital Fund V, L.P. has the right to designate a BCC Designee, no provision
of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment,
by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment shall be
binding on all Purchasers) and Bay City Capital Fund V, L.P. or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought.

 

(g)      Board
Observer Rights. For so long as a Growth Equity Opportunities Fund III, LLC’s (“GEOF”) ownership of
the outstanding Common Stock of the Company is at least five percent (5%), GEOF shall have the right to have a representative (the
“Observer”) attend each meeting of the Board. The Company shall deliver to the Observer notice of such meetings
in accordance with the Company’s Bylaws. Copies of any materials distributed to members of the Board shall likewise be provided
to the Observer in a timely fashion. The Company shall not be required to deliver to the Observer specific information, and may
preclude the Observer from specific discussions of the Board of Directors concerning specific information, that (i) is determined
by the Board of Directors of the Company to be competitively sensitive, (ii) the Board of Directors of the Company determines is
attorney-client privileged and should not, therefore, be disclosed or (iii) the Board of Directors of the Company determines is
reasonably necessary to preserve or protect the exercise of the Board of Directors’ fiduciary duty or to avoid a possible
conflict of interest. GEOF agrees, and any representative of GEOF, including the Observer, will agree, to hold in confidence and
trust and not disclose (other than to GEOF or its affiliates) or use any confidential information provided to or learned by it
in connection with its rights under this letter, provided, that GEOF may give access to such confidential information to its officers,
directors, employees, accountants, counsel and other representatives (collectively, “Representatives”) if each
such Representative is informed of the confidential nature of the information and that the information is subject to a confidentiality
agreement and each such Representative is otherwise under an obligation to keep such confidential information confidential. Each
Observer shall execute a non-disclosure agreement with the Company in form and substance reasonably satisfactory to the Company
prior to commencing his or her role as an Observer. The rights set forth in this Section 6(g) may not be assigned by GEOF without
the prior written consent of the Company.

 

    	-16-

    	 

    

  

7.           OTHER
AGREEMENTS AND COVENANTS

 

(a)      National
Market Listing. Following the Closing, the Company will work with the Purchasers and advisors to qualify for and obtain a full
national market listing of its Common Stock on either the NASDAQ Capital Market or the NYSE MKT. The Company will use commercially
reasonable efforts to qualify and apply for such listing, including effecting a reverse split of its common stock, subject to shareholder
approval, if deemed advisable by a majority of the Board.

 

(b)      Use
of Proceeds. The proceeds from the sale of the Shares and Warrants under this Agreement shall be used for working capital and
general corporate purposes.

 

(c)      Form
D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation
D and, promptly upon request of any Purchaser, to provide a copy thereof. The Company shall take such action as the Company shall
reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers
at each Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser. The Company shall make all filings and reports relating to the
offer and sale of the Securities to the Purchasers required under applicable securities or “Blue Sky” laws of the states
of the United States following each Closing Date.

 

(d)      Reservation
of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to
issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants, in each case issued as of
the Closing. 

 

(e)      Exchange
Act Filings. Until such time that all of the Securities may be sold without the requirement for the Company to be in compliance
with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, the Company covenants to use commercially
reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act.

 

(f)      Integration.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the
Securities for purposes of the rules and regulations of any trading market such that it would require shareholder approval prior
to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

    	-17-

    	 

    

  

(g)      Expenses.
The Company shall pay the reasonable legal and other fees and expenses of the Purchasers incurred in connection with the transactions
contemplated by this Agreement, up to a maximum of $25,000 in the aggregate, whether or not the Closing occurs. In the event the
Closing occurs, the Company shall pay the reasonable legal fees and expenses of the Purchasers incurred in connection with the
transactions contemplated by this Agreement, up to a maximum of $50,000 in the aggregate. Each party shall otherwise bear all costs
and expenses incurred by such party in connection with the transactions contemplated by this Agreement.

 

(h)      Purchaser/Director
Designee Exchange Act Filings.  Each Purchaser and each Director Designee shall be responsible for the filing (and for all
expenses in connection therewith) of required filings under the Exchange Act and all required amendments thereto relating to ownership
of the Securities and appointment as a member of the Board, including any required Forms 3, 4 and 5 and Schedules 13D or 13G (as
applicable). Each Purchaser and each Director Designee shall use commercially reasonable efforts to file such forms within the
time period allowed for such forms under the rules and regulations promulgated by the SEC.

 

8.           PUBLIC
STATEMENTS

 

The Company shall, by 9:00 a.m. (New York
City time) on the trading day immediately following the date of this Agreement, issue a press release disclosing the material terms
of the transactions contemplated hereby. The Company shall file a Current Report on Form 8-K within the time required by Form 8-K
disclosing the material terms of the transactions contemplated hereby, which Form 8-K shall include this Agreement (including conformed
signature pages thereto), the Registration Rights Agreement (including conformed signature pages thereto) and the form of Warrant
as exhibits thereto. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or
without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law.

 

9.           MISCELLANEOUS

 

(a)      Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by the internal laws of the State of Delaware, United States of America, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of Delaware. If any provision of this Agreement shall be invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this
Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.

 

    	-18-

    	 

    

  

(b)      Entire
Agreement. This Agreement and the documents referenced herein and therein constitute the entire agreement among the parties
hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings,
other than those set forth or referred to herein and therein. This Agreement and the documents referenced herein and therein supersede
all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof. Without
limiting the foregoing, it is acknowledged and agreed that (i) Section 6 of this Agreement shall supersede and replace Section
6 of the Common Stock Purchase Agreement, dated May 17, 2013, by and among the Company and the purchasers signatory thereto, as
amended on March 31, 2014 and May 30, 2014 (the “2013 Purchase Agreement”) and (ii) the entry into this Agreement
and the consummation of the transactions contemplated hereby are in lieu of any Subsequent Closings (as defined in the 2013 Purchase
Agreement) and Section 2(b) of the 2013 Purchase Agreement shall have no further effect. Notwithstanding the foregoing, the terms
of any confidentiality agreement entered into between the Company and any Purchaser shall remain in full force and effect.

 

(c)      Amendments
and Waivers. Except as otherwise set forth herein, no provision of this Agreement may be waived, modified, supplemented or
amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least
a majority in interest of the Shares then outstanding (which amendment shall be binding on all Purchasers) or, in the case of a
waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to
any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of
any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of
any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(d)      Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); (iii) upon receipt when delivered by email delivery of a “.pdf” format data file or (iv) upon receipt, when
sent via a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same.
The addresses, facsimile numbers and email addresses for such communications shall be:

 

If to the Company:       Interleukin
Genetics, Inc. 

135 Beaver Street

Waltham, MA 02452

Telephone:  (781) 398-0700

Facsimile:    (781) 398-0720

email:            kkornman@ilgenetics.com

Attention:     Kenneth S. Kornman

                       Chief Executive Officer

 

    	-19-

    	 

    

  

with a copy to:           Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

One Financial Center

Boston, MA 02111

Tel:     (617) 542-6000

Fax:     (617) 542-2241

email:bkeane@mintz.com

Attn: Brian P. Keane, Esq.

 

If to a Purchaser:       To the address
set forth on the signature page to this Agreement.

 

(e)      No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(f)      Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

(g)      Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

(h)      Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger, consolidation or sale of all or substantially all of the Company’s assets). Except
as specifically set forth herein, any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to
the transferred Securities, by the provisions of this Agreement and the documents referenced herein that apply to the Purchasers.

 

(i)      Survival.
Subject to applicable statute of limitations, the representations and warranties contained herein shall survive the Closing and
the delivery of the Securities hereunder. No investigation by or knowledge of a party or its representatives, before or after the
date of this Agreement, will affect in any manner the representations, warranties, covenants or agreements of another party set
forth in this Agreement (or in any document to be delivered in connection with the consummation of the transactions contemplated
by this Agreement) or the rights to rely thereon, and such representations, warranties, covenants and agreements will survive any
such investigation.

 

    	-20-

    	 

    

  

(j)      No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.

 

(k)      Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity or bond) associated with the issuance of such replacement
Securities.

 

(l)      Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any other document
referred to herein, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are
in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement.
Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising
out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding
for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of this Agreement
and the other documents referred to herein.

 

(m)      Business
Day. “Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday
in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other
governmental action to close. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein or in the Registration Rights Agreement shall not be a Business Day, then such action may be taken or such right
may be exercised on the next succeeding Business Day.

 

(n)      Headings.
The headings of this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

(o)      Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

[Remainder of page intentionally left blank.
Signature pages follow.]

 

    	-21-

    	 

    

  

IN WITNESS WHEREOF, the parties hereto have
caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.

  

	 	COMPANY:
	 	 	 
	 	INTERLEUKIN GENETICS, Inc.
	 	 	 
	 	By:	/s/ Kenneth S. Kornman
	 	 	Name:  Kenneth S. Kornman
	 	 	Title:  Chief Executive Officer

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.

SIGNATURE PAGES FOR PURCHASERS FOLLOW.]

 

    	 

    	 

    

  

[PURCHASER SIGNATURE PAGES TO INTERLEUKIN
GENETICS, INC. 

SECURITIES
PURCHASE AGREEMENT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

Name of Purchaser: See Schedule I
hereto.

 

Signature of Authorized Signatory of
Purchaser: __________________________________

 

Name of Authorized Signatory: ____________________________________________________

 

Title of Authorized Signatory: _____________________________________________________

 

Email Address for Notice to Purchaser:
______________________________________________

 

Facsimile Number for Notice to Purchaser: _____________________________________________

 

Address for Notice to Purchaser:

 

Address for Delivery of Securities to Purchaser (if not same
as address for notice):

 

Purchase Price: $_________________

 

Shares of Common Stock: _________________

 

Warrant Shares: __________________

 

EIN Number: __________________

 

[SIGNATURE PAGES CONTINUE]

 

    	 

    	 

    

  

SCHEDULE I

 

The Purchasers

 

	 	 	 	 
	Purchaser	 	Shares	 	 	Warrants	 	 	Purchase Price	 
	Bay City Capital Fund V, L.P. 
	 	 	25,996,552	 	 	 	25,996,552	 	 	$	2,607,454.17	 
	Bay City Capital Fund V Co-Investment Fund, L.P. 
	 	 	495,400	 	 	 	495,400	 	 	$	49,688.62	 
	Growth Equity Opportunities Fund III, LLC 
	 	 	19,868,965	 	 	 	19,868,965	 	 	$	1,992,857.17	 
	Keith C. Stone	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	Charles D. Bryceland	 	 	1,994,018	 	 	 	1,994,018	 	 	$	200,000.01	 
	Stephen DiPalma	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	William Alan Jolly	 	 	747,757	 	 	 	747,757	 	 	$	75,000.03	 
	Michael Jeffrey Reid Charles UAD 4/30/09	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	Daniel Geffken	 	 	249,252	 	 	 	249,252	 	 	$	24,999.98	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	50,099,700	 	 	 	50,099,700	 	 	$	5,024,999.92	 

 

    	 

    	 

    

  

EXHIBIT A

 

See Exhibit 4.1 to the Form 8-K filed on December 23, 2014
(File No. 001-32715)

 

    	 

    	 

    

 

EXHIBIT B

 

See Exhibit 10.2 to the Form 8-K filed on
December 23, 2014 (File No. 001-32715)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]